Current treatments, practical management, and emerging investigational therapies for myelofibrosis

Cancer research · Myelofibrosis

Current treatments, practical management, and emerging investigational therapies for myelofibrosis.

The article reviews current diagnostic frameworks, prognostic models, and treatment strategies for myelofibrosis, including approved JAK inhibitors and emerging investigational therapies. It highlights advances in understanding the molecular pathogenesis, particularly JAK‑STAT signaling, and discusses emerging drug classes, next‑generation JAK inhibitors, mutant calreticulin antibodies, and the evolving management of cytopenias and advanced disease.

This article outlines the therapeutic landscape for a hematologic malignancy that remains largely incurable, emphasizing emerging treatments that could shift standard care and improve patient outcomes.

Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.

Original source

Related signals